

Application Serial No. Unassigned  
Attorney's Docket No. 025219-342

**REMARKS**

Entry of the foregoing amendment to the Specification is requested to comply with the requirements of 37 C.F.R. 1.78(a)(2).

The claims of the subject application have been amended to avoid multiple dependency. Favorable consideration of the subject application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:   
Robert E. Krebs  
Registration No. 25,885

Post Office Box 1404  
Alexandria, Virginia 22313-1404  
(650) 622-2300





Date: August 21, 2001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

In the claims:

Claim 4, 5, 6, 7, 8, 9, and 11 have been amended as follows:

4. Process according to Claim 1, ~~2 or 3~~, in which the enzyme is the Klenow fragment of DNA polymerase.
5. Process according to Claim 1, ~~2 or 3~~, in which the enzyme is a heat-resistant polymerase of a Thermophilus bacterium or terminal transferase or reverse transcriptase.
6. Process according to ~~one of Claims 1 to 5~~, in which the nucleic base is a natural nucleic base chosen from adenine, guanine, cytosine, thymine, uracil, xanthine, hypoxanthine and 2-aminopurine, and derivatives thereof.
7. Process according to ~~any one of Claims 1 to 5~~, in which R<sup>1</sup> corresponds to one of the following formulae:



8. Process according to ~~one of Claims 1 to 7~~, in which the label is chosen from radioactive products, luminescent products, electroluminescent and fluorescent products, molecules capable of coupling with other molecules, molecules which allow interactions of the antigen-antibody type, and enzymatic labels.
9. Process according to ~~any one of the claims 1 to 7~~, in which R<sup>3</sup> is a fluorophore.
11. Process according to Claim 1, ~~2 or 3~~, in which the derivative, the modified morpholino-nucleotide or the chain terminator is compound (I) in monophosphate form.

Claims 18 - 33 have been added.